US biopharmaceutical company Gilead Sciences is to acquire CymaBay Therapeutics for $4.3 billion. Gilead offered to purchase all outstanding shares of CymaBay for $32.50...
15.05.2017
- Swiss pharma company Novartis has exercised an option that gives it global development and commercialization rights to a drug being developed by US biotech Conatus Pharmaceuticals...
